Achieve Life Sciences outlines first half 2027 cytisinicline launch supported by US manufacturing shift and AI-driven commercialization

Earnings Call Insights: Achieve Life Sciences (ACHV) Q4 2025

Management View

• Richard A. Stewart, President, CEO & Executive Director, emphasized the company’s transition from a clinical-stage to a commercially focused enterprise following the NDA submission in June 2025, stating, “Our primary objective now is to make cytisinicline available to the 25 million patients who smoke and nearly 18 million who vape.” He highlighted the FDA acceptance of the NDA for smoking cessation and receipt of the Commissioner’s National Priority Voucher for the vaping indication, providing an accelerated pathway to potential first-in-class approval for vaping cessation.
• Stewart reported progress on regulatory milestones, including the completion of the ORCA-OL long-term exposure trial, which “underlined cytisinicline safety profile, demonstrating strong tolerability and excellent patient satisfaction data.” He also announced the selection of Adare Pharma Solutions as the U.S.-based manufacturer for cytisinicline and initiation of technology transfer, describing it as a move to “increase confidence in our supply-chain security as we advance towards a planned commercial launch of cytisinicline expected in the first half of 2027.”
• Mark Rubinstein, Chief Medical Officer, noted, “2025 has strengthened our clinical and regulatory position significantly. We’re advancing through the FDA’s review process with an active dialogue with the agency.”
• Jaime Xinos, Chief Commercial Officer, detailed the company’s data-driven commercial infrastructure, prioritizing “availability, access, and awareness,” and highlighted advanced analytics, AI tools, and a partnership with Omnicom to expedite marketing material development. She stated, “Every initiative is data-driven, and every decision is tied to measurable impact with the goal of making cytisinicline accessible to the millions of Americans struggling with nicotine dependence.”
• Mark Oki, Chief Financial Officer, reported, “As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $36.4 million. Total operating expenses for the 3 and 12 months ended December 31, 2025, were $14.7 million and $54.9 million, respectively. Our total net loss for the 3 and 12 months ended December 31, 2025, was $14.7 million and $54.7 million, respectively.”

Outlook

• Stewart reaffirmed the company’s near-term priority as “receiving NDA approval and successfully launching cytisinicline for smoking cessation,” with a planned commercial launch in the first half of 2027. He stated, “We remain focused on bringing cytisinicline to patients as quickly as possible.”
• Management described ongoing engagement with payers to finalize pricing and contracting, with Xinos reporting, “We’ve had about 40 touch points with payers in the first quarter. They recognize the differentiated profile of cytisinicline and the clear unmet need.”
• The company continues to prepare for the ORCA-V2 Phase III trial in vaping cessation, with anticipated commencement in the first half of 2026.

Financial Results

• Oki reported $36.4 million in cash, cash equivalents, and marketable securities at year-end 2025. Operating expenses for Q4 and full-year 2025 were $14.7 million and $54.9 million, respectively. Net loss for the same periods was $14.7 million and $54.7 million.
• Compared to the previous quarter, cash decreased from $48.1 million as of September 30, 2025, reflecting continued investment in regulatory, clinical, and commercial preparations.

Q&A

• Thomas Flaten, Lake Street Capital Markets: Asked about the six-month gap between NDA approval and first half 2027 launch, and whether this relates to commercial scale-up or supply. Xinos responded that drug supply is the first consideration, with all trade and distribution preparations ready to go, and highlighted, “The additional 6 months gives us an opportunity to get some additional data into the marketplace and to the scientific community, and also work towards additional partnerships.”
• Flaten also inquired about manufacturing transition to Adare and implications for the NDA. Stewart clarified, “We already made the decision to transfer manufacturing to the U.S. given the geopolitical situation. So, we basically just accelerated that.”
• Jason Butler, Citizens JMP Securities: Questioned health care provider awareness and FDA dialogue on vaping. Xinos explained resource conservation ahead of launch, with broader education to scale as launch approaches. Rubinstein added, “Our discussions with FDA around vaping have largely been around approval for the protocol itself.”
• Brandon Folkes, H.C. Wainwright: Sought clarification on launch timing flexibility and Adare’s role in the NDA. Stewart confirmed Adare’s addition would be post-approval and said, “There’s nothing to read into it other than we got a couple of observations that our third-party manufacturer is currently addressing with the FDA.”
• Folkes asked about payer coverage at launch. Xinos noted, “The Affordable Care Act requires coverage of smoking-cessation treatments,” and described a “slow ramp for the initial 6 months of launch.”
• Justin Walsh, JonesTrading: Asked about raw material supply. Stewart assured, “By the time we get to launch, we believe we’ll have more than 3 years supply of starting material for the amounts required for in-market sales.”
• Walsh also asked about dosing schedule compliance. Rubinstein responded that adherence was high, “over 75%” in trials, with participants finding the regimen manageable.
• John Vandermosten, Zacks: Asked about ICER pricing report and manufacturing partners. Xinos acknowledged awareness of the report but said no pricing has been set. Stewart explained the roles of Sopharma, a European manufacturer, and Adare, with Adare expected to be added to the NDA in the third quarter post-approval.

Sentiment Analysis

• Analysts pressed for clarification on launch timing, manufacturing transition, coverage expectations, and supply chain, indicating a slightly cautious but constructive tone. Multiple questions centered on operational execution and risk mitigation.
• Management maintained a confident and measured tone. Stewart frequently emphasized strategic prudence, supply chain security, and regulatory progress, using phrases such as “we remain focused” and “we are dedicated to this urgent need.”
• Compared to the previous quarter, analyst sentiment was more focused on practical launch execution and supply risks, while management shifted from primarily regulatory progress to operational readiness and commercial buildout.

Quarter-over-Quarter Comparison

• Guidance for cytisinicline launch shifted from third/fourth quarter 2026 in Q3 to first half 2027 in Q4, reflecting a more conservative operational timeline.
• Strategic focus evolved from regulatory milestones and commercial platform development to full-scale operational readiness, supply chain redundancy, and U.S. manufacturing transition.
• Analysts’ questions shifted from protocol design and commercial overlap to tangible launch logistics, supply chain stability, and payer engagement.
• Key financial metrics showed a decrease in cash from $48.1 million in Q3 to $36.4 million at year-end, in line with increased pre-launch investment.
• Management’s tone remained confident but became more detailed on execution and risk mitigation, while analysts increased focus on potential operational bottlenecks.

Risks and Concerns

• Stewart acknowledged FDA manufacturing observations for the NDA-listed manufacturer, stating, “The manufacturer named in the cytisinicline NDA recently had an FDA Good Manufacturing Practices inspection with 2 observations… which are being addressed through an ongoing communication of its remedial action plan with the FDA.”
• Supply chain risk is being mitigated by transitioning to U.S.-based Adare Pharma Solutions and maintaining more than three years’ supply of raw materials.
• Payer coverage and access at launch remain under discussion, with management citing ongoing engagement and Affordable Care Act provisions.
• Pricing has not yet been set, with management deferring specifics pending further payer feedback and market assessment.

Final Takeaway

Achieve Life Sciences is advancing toward a first half 2027 commercial launch of cytisinicline, underpinned by a strategic shift to U.S. manufacturing with Adare Pharma Solutions and robust supply chain contingency. The company continues to execute on digital and AI-driven commercialization, with ongoing regulatory progress and payer engagement. Management remains focused on operational readiness and risk mitigation as it aims to deliver the first FDA-approved nicotine dependence treatment in two decades, addressing significant unmet needs in both smoking and vaping cessation markets.

Read the full Earnings Call Transcript